

## The causal associations between cancers and cardiovascular diseases: a two-sample bidirectional Mendelian randomization analysis

Daoming Zhang, MD, PhD<sup>\*</sup>; Haoyue Li, BS<sup>\*</sup>; Yuan Li, MD, PhD<sup>\*</sup>; Tian Tang, MD, PhD; Zhenming Fu, MD, PhD; Yongfa Zheng, MD, PhD; and Ximing Xu, MD, PhD

Correspondence to: Zhenming Fu, MD; Yongfa Zheng, MD, and Ximing Xu, MD,

Cancer Center, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan, Hubei Province 430060, China. Email: [davidfuzming@whu.edu.cn](mailto:davidfuzming@whu.edu.cn), [Zyf0322@126.com](mailto:Zyf0322@126.com), [doctorxu120@aliyun.com](mailto:doctorxu120@aliyun.com)

<sup>\*</sup>D. Zhang, H. Li and Y Li contributed equally.

**BACKGROUND:** Associations between cancer and cardiovascular disease (CVD) have been reported previously in observational studies. However, the causal relationship between the specific subspecies of the two diseases remains unclear. This study used a two-sample bidirectional MR study to investigate the causal relationship between different types of CVDs and the major types of malignancies and vice-versa.

**METHODS AND RESULTS:** We extracted summary statistics for coronary atherosclerosis, hypertension, hypertrophic cardiomyopathy, heart failure, atrial fibrillation, stroke, and 14 common malignancies from published relevant genome-wide association studies as instrumental variables. We conducted two-sample bidirectional Mendelian randomization (MR) studies to assess the causal relationship between CVD and cancer in which the inverse variance weighting (IVW) method was the main method. Multiple comparison calibration, sensitivity analysis, and heterogeneity analysis were performed to improve the reliability and robustness of the results. The evidence from IVW analyses showed that genetically predicted coronary atherosclerosis was suggestively associated with a decreased risk of endometrial cancer (OR=0.053, 95% CI: 0.004-0.648, P=0.022); hypertension was suggestively associated with an increased risk of oral cavity/pharyngeal cancer (OR=14.872, 95% CI: 1.324-167.053, P=0.029); hypertrophic cardiomyopathy was suggestively associated with a decreased risk of brain cancer (OR=0.479, 95% CI: 0.257-0.890, P=0.020); any stroke was suggestively associated with a decreased risk of breast cancer (OR=0.798, 95% CI: 0.669-0.952, P=0.012) and prostate cancer (OR=0.844, 95% CI: 0.737-0.966, P=0.014) since their significance weakened after multiple

testing. In the reverse MR analysis, bladder cancer was associated with an increased risk of coronary atherosclerosis (OR=1.426, 95% CI: 1.051- 1.934, P= 0.023) and hypertension (OR=1.689, 95% CI: 1.115-2.557, P=0.013); pancreatic cancer was associated with an increased risk of any stroke (OR= 1.047, 95% CI: 1.005-1.090, P= 0.027), losing significance after multivariate testing. Prostate cancer was significantly associated with an increased risk of heart failure (OR= 1.030, 95% CI: 1.009-1.053, P= 0.006); cervical cancer was significantly associated with an increased risk of any stroke (OR= 8.751686e+03, 95% CI: 35.043-2.185650e+06, P= 0.001).

**CONCLUSIONS:** Causal relationships for specific types of CVD and cancer were found in this MR Study, although some were suggestive. This study provides ideas for the follow-up management of these two common chronic diseases.

**Keywords:** cardiovascular disease, Mendelian randomization, cancer, causal relationship

## CLINICAL PERSPECTIVE

### What Is New?

- Some observational studies have shown that cardiovascular diseases (CVDs) and cancer have complex causal relationships dominated by positive associations. However, the role of genetic factors in their comorbidities remains unclear.
- In this study, by utilizing data from genome-wide association studies, we identified a significant genetic correlation between multiple groups of specific classes of CVDs and specific types of malignancy, along with the shared risk snp. Some of the results are contrary to previous reports and warrant further research. These findings could provide insights into the shared genetic architecture between CVD and cancer.

### What Are the Clinical Implications?

This study adds to the understanding of the underlying causal relationships of different phenotypes of CVD and cancer, with implications for the prediction and prevention of these common comorbidities.

Cardiovascular disease (CVD) and cancer are common diseases worldwide, seriously affecting survival time and quality of life. Malignant tumor is the second leading cause of death globally. In 2020, 19.29 million new cancer cases worldwide were reported, with 9.96 million deaths. With an aging global population, the cancer burden is expected to increase by 47% in 2040 compared to 2020.<sup>1</sup> Cancer threatens human health and poor quality of life. The risk factors are highly complex and heterogeneous. Cancer prevention focuses on specific risk factors such as tobacco use, diet, lifestyle habits, and carcinogen infections.<sup>2-4</sup> CVDs are the leading cause of the global disease burden. The number of deaths attributed to CVD increased by 18.7% from 2010 to 2020.<sup>5</sup> Currently recognized common risk factors for CVDs include

hypertension, hyperlipidemia, obesity, diabetes, smoking, and alcohol consumption.<sup>6</sup> The coexistence or sequential occurrence of the two diseases is common. The intricate potential causal relationship between them has long attracted the interest of researchers and related epidemiological studies have been reported; however, these have focused on specific types of studies in two categories of diseases.

In a prospective follow-up study of individuals who did not have cancer at baseline, the prevalence of CVDs and occurrence of interim cardiovascular events were not associated with a higher risk for subsequent cancer development. However, ideal cardiovascular fitness is associated with a lower risk of future cancer. Studies have shown the association between CVD and future cancer which is attributed to shared risk factors.<sup>7</sup> An observational study of long-term CVD risk in 1,26,120 cancer survivors suggests that cancer therapies, particularly chemotherapy, rather than cancer itself, play a major role in CVD risk.<sup>8</sup> In contrast, in a Canadian study, newly diagnosed cancer was associated with higher risks for cardiovascular mortality, acute myocardial infarction, stroke, and heart failure after adjustment for covariates including age, sex, hypertension, diabetes, dyslipidemia, and prior CVD.<sup>9</sup> Possible explanations for the conflicting results to date include the degree to which some studies were effective in adjusting for shared risk factors and the vulnerability of previous studies to biases inherent in observational studies, such as residual confounding and reverse causality. Simultaneously, the intricate associations between different types of CVDs and malignancies cannot be studied generally without a breakdown.

Mendelian randomization (MR) estimates the causal relationship between exposure and outcome by using instrumental variables (IVs) strongly associated with exposure and strengthens the causal inference by controlling for non-genetic environmental confounders and reverse causality. MR analysis, due to random combinations of alleles during meiosis, and germ cell line genetic variation fixed at conception, is less susceptible to conventional confounders and reverse causation. Currently, no large-scale MR study examining the association between multiple CVDs and multiple malignancies has been reported.

This study used a two-sample bidirectional MR to investigate the causal relationship between different types of CVDs and the major types of malignancies and vice-versa.

## **METHODS**

### **Study Design**

A two-sample bidirectional MR study was designed to explore the impact of CVDs on the risk of common cancers as shown in **Figure 1**. The bidirectional MR study was based on three assumptions.<sup>10</sup> All data were publicly available for both males and females and predominantly European population. The study adhered to the latest Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomisation (STROBE-MR) guidelines.<sup>11</sup> The included studies were approved by the relevant ethical review boards, and informed consent was obtained

from the participants.

Single-nucleotide polymorphism (SNP) selection for CVDS was from genome-wide association studies (GWASs) of the UK Biobank, the FinnGen study, and other large consortia (**Table S1**). For CVDs, we detected six phenotypes including coronary atherosclerosis (361,194 participants with 14,334 cases and 346,860 controls), hypertension (463,010 participants with 54,358 cases and 408,652 controls), hypertrophic cardiomyopathy (337,159 participants with 71 cases and 337,088 controls), heart failure (977,323 participants with 47,309 cases and 930,014 controls), atrial fibrillation (463,010 participants with 5,669 cases and 457,341 controls), and any type of stroke (446,696 participants with 40,585 cases and 406,111 controls). Four criteria were used to select suitable SNPs as eligible IVs. First, selected SNPs were required to be suggestive of genome-wide significance ( $p < 5 \times 10^{-8}$ ). Second, independence among the selected SNPs was assessed based on paired linkage disequilibrium. For  $r^2 < 0.001$  and clump window=10000-kb, independent SNPs without linkage were selected.<sup>12</sup> SNPs with pleiotropic effects within or near the FTO gene were excluded.<sup>13</sup> Third, F-statistics were calculated to verify the strength of individual SNPs. SNPs were considered strong enough to mitigate the effect of potential bias when the F-statistic was greater than 10. Fourth, to avoid potential pleiotropic effects, the PhenoScanner database was queried for secondary phenotypes for each SNP using a threshold of  $P < 1 \times 10^{-5}$ , and SNPs associated with outcome confounders were removed.<sup>14</sup>

### **Common Data Sources of Cancer**

We selected 14 specific types of tumors and their data sources and related information are presented in **Table S1**. The GWAS summary statistics of oral/pharyngeal cancer (4,671 participants with 2,342 cases and 2,329 controls) were obtained from the Oncoarray oral cavity and oropharyngeal cancer consortium.<sup>15</sup> Thyroid cancer data (1,080 participants including 649 patients and 431 controls) were extracted from the report by Kohler et al.<sup>16</sup> The GWAS summary data of brain cancer (33,832 participants including 15,748 patients and 18,084 controls) were obtained from Burrows et al. GWAS summary data for lung cancer (27,209 participants including 11,348 patients and 15,861 controls) were extracted from the International Lung Cancer Association (ILCCO).<sup>17</sup> The GWAS summary data of breast cancer (33,832 participants including 15,748 patients and 18,084 controls) was obtained from the Breast Cancer Association Consortium (BCAC).<sup>18</sup> Data on ovarian cancer (66,450 participants including 25,509 patients and 40,941 controls) were extracted from the Ovarian Cancer Associations Consortium (OCAC).<sup>19</sup> Pancreatic cancer summary data (3,835 participants including 1,896 patients and 1,939 controls) were obtained from PanScan.<sup>20</sup> Stomach cancer data were derived from the FinnGen study, including information on 633 patients and 218,159 controls. The GWAS summary data of liver cancer (372,184 participants including 168 patients and 372,016 controls) were obtained from the UK Biobank study. Data on colon cancer (361,194 participants including 2,226 patients and 358,968 controls) were extracted from the UK Biobank study. Data on endometrial cancer (121,885 participants including 12,906 patients and

108,979 controls) were obtained from a meta-GWAS published by O'Mara et al.<sup>21</sup> The summary data on prostate cancer (140,254 participants including 79,148 patients and 61,106 controls) were from a GWAS published by Schumacher et al.<sup>22</sup> Bladder cancer data were derived from a report by Burrows et al. which included information on 1,279 patients and 372,016 controls. The cervical cancer summary data included 563 patients and 198,523 controls. Since SNPs identified by GWAS in a proportion of cancers rarely reached the genome-wide significance level of  $P < 5 \times 10^{-8}$ , we selected SNPs ( $P < 1 \times 10^{-5}$ ) as the IVs for these cancer species (**Table S2**).

### Statistical Analysis

Inverse-variance weighted (IVW) method was used as the main MR Method to estimate the interassociation. This approach calculates and combines Wald ratios for each SNP from meta-analyses to estimate the overall effect of exposure on outcomes.<sup>23</sup> The MR-Egger, weighted median, and weighted mode analysis methods were used to supplement and increase the stability of the results. The MR-Egger method was used to assess the horizontal pleiotropy of selected IVs, When the Egger intercept of the linear regression was close to 0, there was no directional pleiotropy of the IVs, and the exclusivity hypothesis was considered valid.<sup>24</sup> The weighted-median method can provide valid estimates if more than 50% of the information comes from valid IVs.<sup>25</sup> The MR-Steiger method was analyzed to monitor the direction of potential causal effects between assigned exposures and outcome risks.

In terms of sensitivity analysis, Cochran's Q-test was used to quantitatively analyze the magnitude of heterogeneity among genetic IVs, if the heterogeneity of the results was not significant ( $P > 0.05$ ), and the fixed effect model of IVW was used for MR analysis.<sup>26</sup> MR Pleiotropy RESidual Sum and Outlier (MRPRESSO) and inverse variance weighted estimates were generated after the removal of outliers. The p-value of the MRPRESSO distortion test was used to assess significant differences between the estimates before and after outlier correction.<sup>27</sup> Horizontal pleiotropy of SNPs was assessed using the MR Egger intercept method, if the intercept term was close to 0 ( $P < 0.05$ ), and the effect of genetic pleiotropy was considered to be small. Leave-one-out sensitivity analysis was performed to test whether the results were influenced by any single SNP. For determining the exposure factors in the above meaningful relationships, the data in the corresponding FinnGen database were re-obtained, and MR analysis was performed. Meta-analysis was used to combine the association results from different databases. Correction for multiple testing was performed using the false discovery rate based on the BenjaminiHochberg method. All statistical tests were two-sided and were performed with the TwoSampleMR and MR-PRESSO packages in R Software 3.6.1.

### Ethics

As all studies included had been approved by their independent review boards, no additional ethical approval was required in our studies based on pooled curated data.

## RESULTS

### Screening SNPs

We screened SNPs associated with coronary atherosclerosis, hypertension, hypertrophic cardiomyopathy, heart failure, atrial fibrillation, and any other stroke using GWAS data. After querying the PhenoScanner database, some SNPs were eliminated due to associations with confounding factors for cancer occurrence, and SNPs associated with BMI and obesity were also excluded. Finally, the F-statistic >10 used to screen SNPs showed no weak instrument bias and were selected as IVs for MR analysis (Table S2).

### Causal Effects of Coronary Atherosclerosis on Common Cancers

The IVW method was used to analyze the effects of six types of CVDs on 14 common cancers. The results of MR analyses are presented in Figure 2 and Table S3. The results showed that genetically predicted coronary atherosclerosis was associated with a decreased risk of endometrial cancer (OR=0.053, 95% CI: 0.004-0.648, P=0.022); hypertension was associated with an increased risk of oral cavity/pharyngeal cancer (OR=14.872, 95% CI: 1.324-167.053, P=0.029); hypertrophic cardiomyopathy was associated with a decreased risk of brain cancer (OR=0.479, 95% CI: 0.257-0.890, P=0.020); other strokes were associated with a decreased risk of breast cancer (OR=0.798, 95% CI: 0.669-0.952, P=0.012) and prostate cancer (OR=0.844, 95% CI: 0.737-0.966, P=0.014). Unfortunately, the significance of each causal relationship was attenuated after adjustment for multiple testing. After MR-PRESSO analysis for outlier detection, three outliers were identified in the association between coronary atherosclerosis and endometrial cancer (OR=0.095, 95% CI: 0.013-0.679, P=0.019), and one outlier was identified in the association between any stroke and breast cancer (OR=0.745, 95% CI: 0.652-0.853, P= 1.85E-05)(Table S5). The results of heterogeneity analyses and horizontal pleiotropy tests are shown in Tables S4 and S6. For the association between hypertension and oral cavity/pharyngeal cancer, no heterogeneity among estimates of individual SNPs was detected in the Cochran Q-test (Q= 54.144; P= 0.545) and no pleiotropy was observed in the MR-Egger regression analysis (intercept P=0.875;), the same characteristic was applied to determine the association between any stroke and breast cancer. The scatter plots of the objects with statistically significant correlations (colored lines indicate the slopes of different regression analyses) are shown in Figure S1, and the forest plot of the results of the leave-one-out method is shown in Figure S2. MR-Steiger analysis was used to further verify the directionality of the above associations, and the results showed that the directions of causal associations between coronary atherosclerosis and endometrial cancer, hypertrophic cardiomyopathy and brain cancer, and other strokes, and prostate cancer were statistically significant (Table S11).

### Causal Effects of Common Cancers on Coronary Atherosclerosis

Associations of genetic liability to cancer with the risk of coronary atherosclerosis were analyzed by the IVW method, and results of MR analyses are presented in

**Figure 3 and Supplementary Table S7.** Genetically predicted bladder cancer was significantly associated with an increased risk of coronary atherosclerosis (OR=1.426, 95% CI: 1.051- 1.934, P= 0.023) and hypertension (OR=1.689, 95% CI: 1.115-2.557, P=0.013); pancreatic cancer was significantly associated with an increased risk of other strokes (OR= 1.047, 95% CI: 1.005-1.090, P= 0.027) but lost significance after multivariate testing. The following conclusions were stable after multivariate testing: prostate cancer was significantly associated with an increased risk of heart failure (OR= 1.030, 95% CI: 1.009-1.053, P= 0.006); cervical cancer was significantly associated with an increased risk of other strokes (OR= 8.751686e+03, 95% CI: 35.043-2.185650e+06, P= 0.001);

No outlier was identified after MR-PRESSO analysis (**Table S9**). The results of heterogeneity analyses and horizontal pleiotropy tests are shown in **Tables S8 and S10**. For the association between prostate cancer and heart failure, no heterogeneity among estimates of individual SNPs was detected in the Cochran Q-test (Q= 113.31; P= 0.154) and no pleiotropy was observed in the MR-Egger regression analysis (intercept P=0.591). The same characteristic was applied to an association between pancreatic cancer and other strokes and cervical cancer and other strokes. MR-Steiger analysis showed that the directions of causal associations were statistically significant (**Table S11**).

For the exposure factors in the above meaningful relationships, data from the corresponding FinnGen database were re-obtained and MR analysis was performed (**Table S12**). Coronary atherosclerosis was found to be significantly associated with an increased risk of endometrial cancer (OR= 1.1223, 95% CI: 1.004- 1.254, P= 0.042), however, this result was contrary to that obtained from the IEU data. Bladder cancer was significantly associated with an increased risk of hypertension (OR= 1.002, 95% CI: 1.001- 1.004, P= 0.009), the same as that obtained from the IEU data. Meta-analysis results are shown in **Table 1** after merging the association results from different databases.

## DISCUSSION

In our study, some potential causal relationships between CVD and cancer were found by bidirectional two-sample MR analysis. Hypertension increases the risk of oral cancer. Hypertrophic cardiomyopathy was significantly associated with a decreased risk of brain cancer. Stroke was significantly associated with a decreased risk of breast cancer and prostate cancer. Unfortunately, the significance of these causal associations reduced after adjustment for multiple testing, although their directionality was supported by the MR-Steiger analysis. For effects of common cancers on coronary atherosclerosis, we found that patients with bladder cancer were more likely to have coronary atherosclerosis and hypertension; pancreatic cancer increased the risk of stroke; these associations were attenuated after adjustment for multiple comparisons. The association of prostate cancer with increased risk for heart failure and for cervical cancer with increased risk for stroke remained robust after multiple testing. In the MR analysis of exposure factors obtained from the FinnGen database, an increased risk of bladder cancer for hypertension was also observed. MR

analysis results suggest that partial genetic prediction of cancer subtypes and CAD subtype correlation warrant further study for the potential biological mechanism.

Several retrospective studies have investigated the effect of CVD on the risk of cancer.<sup>28</sup> Framingham heart study (Framingham) and prevention of renal and vascular disease research (PREVEND) involving 20305 participants aged 36 to 64 years were assessed.<sup>29</sup> The most common cancer subtypes during follow-up were those of the gastrointestinal (20%) tract, lungs (11%), prostate (16%), and breasts (18%). Those who maintained a heart-healthy lifestyle showed a reduced risk of CVD and a simultaneously lowered risk of cancer. An association between a heart-healthy lifestyle and lower cancer risk has been shown, and vice versa, a heart-unhealthy lifestyle is associated with higher cancer risk. Traditional CVD risk factors, such as age, male sex, smoking, or a history of smoking and diabetes are linked to increased risk of cancer, independent of the correlation. A retrospective cohort study with data derived from IBM's MarketScan health insurance database<sup>30</sup> showed that compared with patients without CVD, patients with CVD had a significantly higher risk of developing a new cancer. Sensitivity analysis was further performed with adjustment for smoking history and BMI, and the results remained significant. The results of subgroup analysis by tumor type suggested that the atherosclerotic CVD group could lead to an increased risk of lung cancer, bladder cancer, central nervous system cancer, and hematologic cancer. A Korean study reporting the association between hypertension and upper aerodigestive tract cancer found that patients with untreated hypertension showed the highest risk of developing oral cancer.<sup>31</sup> This conclusion is consistent with the results of our study. Many similar retrospective studies have concluded that CVD is a high-risk factor for cancer development but it is interesting that hypertrophic cardiomyopathy is a protective factor for the brain and stroke was significantly associated with a decreased risk of breast cancer and prostate cancer as evidenced in the MR analysis. There are no studies on the effect of hypertrophic cardiomyopathy on the risk of cancer, and reports suggest that cancer therapy induces cardiomyopathy.<sup>32</sup> Interestingly, an MR for women's health study found an inverse association between coronary artery disease and breast cancer.<sup>33</sup> Several factors suggested in the study may have contributed to these results. First, patterns may reflect ascertainment bias and competing risk. People at high risk of coronary heart disease (CHD) may live a shorter duration than those at low risk and are less likely to be diagnosed with breast cancer in their lifetime. Secondly, CAD treatment may be useful in preventing breast cancer. Third, the genetic mechanisms underlying CHD may have a protective effect on breast cancer. These explanations may also apply to the relationship of negative correlations in our study.

The phenomenon that cancer patients are more likely to suffer from CVDs is widely accepted by scientists but previous studies have found that this outcome is mainly caused by cardiovascular damage caused by anti-tumor treatment.<sup>34</sup> The two diseases have common risk factors, such as old age, smoking, obesity, lack of exercise, etc.<sup>35</sup> Cancer itself increases the risk of coronary thrombosis due to abnormal coagulation, platelet activation, and endothelial dysfunction.<sup>36</sup> Recently patients with cancer and relative cardiac hypertrophy before receiving cancer treatment were studied<sup>37</sup> and



abnormalities in baseline cardiac function before antitumor therapy were reported.<sup>38</sup> Therefore, cancer patients may be predisposed to CVD independent of the treatment. A study using data from the SEER database found that patients with breast cancer treated without chemotherapy or radiotherapy had a higher risk of developing a new CVD compared with the general population, especially when treated without tumor resection.<sup>39</sup> This suggests that in addition to the side effects of radiotherapy and chemotherapy, genetic factors caused by cancer itself also have an impact on the subsequent occurrence of cardiovascular diseases. In a recent follow-up study of diagnosed UK Biobank participants, nearly one-third of cancer survivors had CVDs such as ischemic heart disease, stroke, arrhythmia (atrial fibrillation), and heart failure. The highest incidence of CVD was in patients with lung cancer (49.5%), blood cancer (48.5%), and prostate cancer (41%), and the risk of incident CVD was confirmed to be independent of traditional cardiovascular risk factors.<sup>40</sup> This study has several strengths. First, it is the first systematic and comprehensive inclusion of cancer and CVD using a bidirectional MR analysis. Second is the MR study design, which alleviates confounding factors and reverses the causal bias. Our study yielded pooled data from large genetic studies in European populations, so the results are unlikely to be affected by population structure bias. Furthermore, high-quality data sources ensure adequate statistical power and robustness of the findings.

## STUDY LIMITATIONS

The limitations of the study should be considered. First, we cannot completely rule out the possibility that exposure to disease-associated SNPs affects the outcome of disease through other causal pathways, despite testing for horizontal pleiotropic effects and handling of outliers. Second, because this study only included Europeans, the generalizability of the findings is limited to other populations. Third, due to the use of summary data, we cannot draw nonlinear correlations or perform layered effect analysis. Our study was mainly based on available GWAS data. In the absence of GWAS for subtypes (pathological type, subsite, molecular subtype) in different cancers, it is difficult to infer the differential effect of further subtyping on causality. This study explored the relationship between cancer and CVD from a genetic perspective, and the mechanism different from previously determined common risk factors needs further investigation.

## CONCLUSIONS

In conclusion, this study is the first to analyze the causal relationship between common CVD and common cancer using a bidirectional MR method. We found several sets of associations as described above, although most of the conclusions are suggestive, especially that hypertrophic cardiomyopathy is a protective factor for brain and prostate cancer; it is contrary to previous findings. This study is expected to provide analysis ideas and directions for clinical management of chronic diseases and cancer.

## ARTICLE INFORMATION

## **Affiliations**

Cancer Center, Renmin Hospital (D.Z., Y.L., T.T., Z.F., Y.Z., X.X.); and CCU, Renmin Hospital (H.L.), Wuhan University, Hubei, China.

## **Acknowledgments**

This work was funded by the National Natural Science Foundation of China(31971166). We thank the included databases and the authors for generously making the data publicly available. We would like to thank KetengEdit ([www.ketengedit.com](http://www.ketengedit.com)) for its linguistic assistance during the language modification of this manuscript.

## **Sources of Funding**

This work was funded by the National Natural Science Foundation of China(31971166).

## **Disclosures**

None.

## **Supplemental Material**

Tables S1–S12

Figures S1–S2

## **Contributors**

Conception and design of the study: DMZ, XMX and YFZ; Collection of the data: HYL, YL, TT and DMZ; Analysis and interpretation of data: ZMF, YL, HYL and YFZ; Manuscript writing: DMZ, ZMF; Manuscript revising: XMX, YFZ and ZMF. Access and verify of the underlying data: TT, XMX.

## **Data and Resource Availability**

All data used in this study were obtained from GWAS summary statistics, which are publicly released by the Genetic consortium.

## **References**

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71:209-249. doi: 10.3322/caac.21660
2. Levitz JS, Bradley TP, Golden AL. Overview of smoking and all cancers. *Med Clin North Am.* 2004;88:1655-xiii. doi: 10.1016/j.mcna.2004.07.005
3. Zhang J, Wang P, Li J, Mendola P, Sherman S, Ying Q. Estimating population exposure to ambient polycyclic aromatic hydrocarbon in the United States - Part II: Source apportionment and cancer risk assessment. *Environ Int.* 2016;97:163-170. doi: 10.1016/j.envint.2016.08.024

4. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. *Nat Rev Clin Oncol*. 2009;6:638-647. doi: 10.1038/nrclinonc.2009.146
5. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. 2022;145:e153-e639. doi: 10.1161/CIR.0000000000001052
6. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*. 2020;76:2982-3021. doi: 10.1016/j.jacc.2020.11.010
7. Lau ES, Paniagua SM, Liu E, Jovani M, Li SX, Takvorian K, Suthahar N, Cheng S, Splansky GL, Januzzi JL Jr, Wang TJ, Vasani RS, Kreger B, Larson MG, Levy D, de Boer RA, Ho JE. Cardiovascular Risk Factors are Associated with Future Cancer. *JACC CardioOncol*. 2021;3:48-58 . doi: 10.1016/j.jacc.2020.12.003
8. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, Kelly SP, Zaorsky NG. A population-based study of cardiovascular disease mortality risk in US cancer patients. *Eur Heart J*. 2019;40:3889-3897. doi: 10.1093/eurheartj/ehz766
9. Paterson DI, Wiebe N, Cheung WY, Mackey JR, Pituskin E, Reiman A, Tonelli M. Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study. *JACC CardioOncol*. 2022;4:85-94. doi: 10.1016/j.jacc.2022.01.100
10. Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. *JAMA*. 2017;318:1925–1926. doi : 10.1001/jama.2017.17219
11. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *JAMA*. 2021;326:1614-1621. doi: 10.1001/jama.2021.18236
12. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics*. 2015;31:3555-3557. doi: 10.1093/bioinformatics/btv402
13. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science*. 2007;316:889-894. doi: 10.1126/science.1141634
14. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, Butterworth AS, Staley JR. PhenoScanner V2: an expanded tool for searching

- human genotype-phenotype associations. *Bioinformatics*. 2019;35:4851-4853 . doi: 10.1093/bioinformatics/btz469
15. Lesseur C, Diergaard B, Olshan AF, Wünsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, Zaridze D, Johansson M. Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. *Nat Genet*. 2016;48:1544-1550. doi: 10.1038/ng.3685
  16. Köhler A, Chen B, Gemignani F, Elisei R, Romei C, Figlioli G, Cipollini M, Cristaudo A, Bambi F, Hoffmann P, Herms S, Kalemba M, Kula D, Harris S, Broderick P, Houlston R, Pastor S, Marcos R, Velázquez A, Jarzab B, Hemminki K, Landi S, Försti A. Genome-wide association study on differentiated thyroid cancer. *J Clin Endocrinol Metab*. 2013;98:E1674-E1681. doi: 10.1210/jc.2013-1941
  17. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR, Houlston RS. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nat Genet*. 2008;40:616-622. doi: 10.1038/ng.109
  18. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nat Genet*. 2011;43:1210-1214. doi: 10.1038/ng.985
  19. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet*. 2017;49:680-691. doi: 10.1038/ng.3826
  20. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. *Nat Genet*. 2009;41:986-990. doi: 10.1038/ng.429
  21. O'Mara TA, Glubb DM, Amant F, Annibaldi D, Ashton K. Identification of nine new susceptibility loci for endometrial cancer. *Nat Commun*. 2018;9:3166. doi: 10.1038/s41467-018-05427-7
  22. Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet*. 2019;51:363. doi: 10.1038/s41588-018-0330-6
  23. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med*. 2008;27:1133-1163. doi: 10.1002/sim.3034
  24. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44:512-525. doi: 10.1093/ije/dyv080
  25. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. *Epidemiology*. 2017;28(1):30-42. doi:

- 10.1097/EDE.0000000000000559
26. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat Med*. 2017;36:1783-1802. doi: 10.1002/sim.7221
  27. Verbanck M, Chen CY, Neale B, Do R. Publisher Correction: Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet*. 2018;50(8):1196. doi: 10.1038/s41588-018-0164-2
  28. Mulder FI, Horváth-Puhó E, van Es N, et al. Arterial Thromboembolism in Cancer Patients: A Danish Population-Based Cohort Study. *JACC CardioOncol*. 2021;3:205-218. doi: 10.1016/j.jacc.2021.02.007
  29. Paterson DI, Wiebe N, Cheung WY, Mackey JR, Pituskin E, Reiman A, Tonelli M. Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study. *JACC CardioOncol*. 2022;4(1):85-94. doi: 10.1016/j.jacc.2022.01.100
  30. [https://www.ahajournals.org/doi/10.1161/circ.146.suppl\\_1.11425](https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.11425).
  31. Seo JH, Kim YD, Park CS, Han KD, Joo YH. Hypertension is associated with oral, laryngeal, and esophageal cancer: a nationwide population-based study. *Sci Rep*. 2020;10:10291. doi: 10.1038/s41598-020-67329-3
  32. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. *Circulation*. 2019;140:31-41. doi: 10.1161/CIRCULATIONAHA.118.037934
  33. Xiao B, Velez Edwards DR, Lucas A, Drivas T, Gray K. Inference of Causal Relationships Between Genetic Risk Factors for Cardiometabolic Phenotypes and Female-Specific Health Conditions. *J Am Heart Assoc*. 2023;12(5):e026561. doi: 10.1161/JAHA.121.026561
  34. Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. *Int J Cardiol*. 2019;280:163-175. doi: 10.1016/j.ijcard.2019.01.038
  35. Liu D, Ma Z, Yang J, Zhao M, Ao H, Zheng X, Wen Q, Yang Y, You J, Qiao S, Yuan J. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. *Aging (Albany NY)*. 2019;11:7948-7960. doi: 10.18632/aging.102301
  36. Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. *J Cardiol*. 2018;72:89-93. doi: 10.1016/j.jjcc.2018.02.011
  37. Maayah ZH, Takahara S, Alam AS, Ferdaoussi M, Sutendra G, El-Kadi AOS, Mackey JR, Pituskin E, Paterson DI, Dyck JRB. Breast cancer diagnosis is associated with relative left ventricular hypertrophy and elevated endothelin-1 signaling. *BMC Cancer*. 2020;20:751. doi: 10.1186/s12885-020-07217-1
  38. Tadic M, Genger M, Baudisch A, Kelle S, Cuspidi C, Belyavskiy E, Burkhardt F, Venneri L, Attanasio P, Pieske B. Left Ventricular Strain in Chemotherapy-Naive and Radiotherapy-Naive Patients With Cancer. *Can J Cardiol*. 2018;34:281-287. doi: 10.1016/j.cjca.2017.11.018

39. Guan X, Wei R, Yang R, Lu Z, Liu E, Zhao Z, Chen H, Yang M, Liu Z, Jiang Z, Wang X. Risk and Prognosis of Secondary Bladder Cancer After Radiation Therapy for Rectal Cancer: A Large Population-Based Cohort Study. *Front Oncol.* 2021;10:586401. doi: 10.3389/fonc.2020.586401
40. Raisi-Estabragh Z, Cooper J, McCracken C, Crosbie EJ, Walter FM, Manisty CH, Robson J, Mamas MA, Harvey NC, Neubauer S, Petersen SE. Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer. *Heart.* 2023;109:1007-1015. doi: 10.1136/heartjnl-2022-321888

It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).




Figure 1. Study design. Dashed lines indicate a pleiotropic or direct causal relationship between exposure and outcome.




Figure 2. Associations of genetic liability to cardiovascular diseases with risk of cancers in the primary analysis.

It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).




Figure 3. Associations of genetic liability to cancers with risk of cardiovascular diseases in the primary analysis.



Table1. Meta-analysis results after merging the association results from different databases

source	exposure	outcome	SNPs	P	OR	LCI	UCI
IEU	Coronary atherosclerosis	Endometrial cancer	31	<b>0.022</b>	0.053	0.004	0.648
finngen	Coronary atherosclerosis	Endometrial cancer	40	<b>0.042</b>	1.122	1.004	1.254
Combined				0.449	0.321	0.017	6.092
IEU	Hypertension	Oral cavity/pharyngeal cancer	60	<b>0.029</b>	14.872	1.324	167.053
finngen	Hypertension	Oral cavity/pharyngeal cancer	107	0.075	0.834	0.683	1.019
Combined				0.112	0.851	0.697	1.038
IEU	Hypertrophic cardiomyopathy	Brain cancer	2	<b>0.020</b>	0.479	0.257	0.890
finngen	Hypertrophic cardiomyopathy	Brain cancer	3	0.411	1.000	1.000	1.001
Combined				0.413	1.000	1.000	1.001
IEU	Any stroke	Breast cancer	8	<b>0.012</b>	0.798	0.669	0.952
finngen	Any stroke	Breast cancer	11	0.647	0.989	0.943	1.037
Combined				0.274	0.975	0.931	1.021
IEU	Any stroke	Prostate cancer	8	<b>0.014</b>	0.844	0.737	0.966
finngen	Any stroke	Prostate cancer	11	0.782	1.009	0.948	1.073
Combined				0.439	0.978	0.924	1.035
IEU	Bladder cancer	Coronary atherosclerosis	34	<b>0.023</b>	1.426	1.051	1.934
finngen	Bladder cancer	Coronary atherosclerosis	23	0.075	1.001	1.000	1.002
Combined				0.074	1.001	1.000	1.002
IEU	Bladder cancer	Hypertension	35	<b>0.013</b>	1.689	1.115	2.557
finngen	Bladder cancer	Hypertension	25	<b>0.009</b>	1.002	1.001	1.004
Combined				<b>0.009</b>	1.003	1.001	1.004
IEU	Prostate cancer	Heart failure	101	<b>0.006</b>	1.030	1.009	1.053
finngen	Prostate cancer	Heart failure	31	0.386	0.989	0.963	1.015
Combined				0.123	1.013	0.997	1.030
IEU	Pancreatic cancer	Any stroke	6	<b>0.027</b>	1.047	1.005	1.090
finngen	Pancreatic cancer	Any stroke	14	0.887	1.002	0.971	1.035
Combined				0.138	1.019	0.994	1.045
IEU	Cervical cancer	Any stroke	21	<b>0.001</b>	8751.686	35.043	2185650.000
finngen	Cervical cancer	Any stroke	8	0.497	0.991	0.964	1.018
Combined				0.508	0.991	0.964	1.018

Abbreviation: SNPs, Single nucleotide polymorphisms; OR, Odds ratio; LCI, Lower confidence interval; UCI, Upper confidence interval.